Pulmonary Hypertensive Vasculopathy In Parenchymal Lung Diseases And/Or Hypoxia

Pulmonary hypertension (PH) with complicating chronic lung diseases and/ or hypoxia falls into group 3 of the updated classification of PH. Patients with chronic obstructive lung disease (COPD), diffuse lung disease (such as idiopathic pulmonary fibrosis (IPF)) and with sleep disordered breathing are particularly exposed to the risk of developing PH. Although PH in such a context is usually mild, a minority of patients exhibit severe haemodynamic impairment, defined by a mean pulmonary arterial pressure (mPAP) of >= 35 mmHg or mPAP values ranging between 25 mmHg and 35 mmHg with a low cardiac index (< 2 L . min(-1) . m(-2)). The overlap between lung parenchymal disease and PH heavily affects life expectancy in such a patient population and complicates their therapeutic management. In this review we illustrate the pathological features and the underlying pathophysiological mechanisms of pulmonary circulation in chronic lung diseases, with an emphasis on COPD, IPF and obstructive sleep apnoea syndrome.